Quinones (e.g. vitamin K) work in a manner opposite to SSRI drugs, yet surprisingly (not!) have antidepressant effects

Many of my readers know about the antidepressant drug tianeptine. When it was first approved, its official mechanism of action was declared to be a selective serotonin reuptake enhancement (SSRE), which directly contradicted the mainstream medical dogma that low serotonin (5-HT) caused depression, and that inhibiting 5-HT uptake with the SSRI drugs would have an antidepressant effects. This “contradiction” is what prevented tianeptine from being approved as an antidepressant in the most Western countries. However, the drugs was still considered a threat to SSRI sales, so within a few years after tianeptine entered clinical use, a multitude of studies were published claiming that tianeptine was not really an SSRE, and that its antidepressant effects are due to an unknown mechanism. Some additional studies came out after that, claiming that tianeptine’s effects may be due to its ability to antagonize glutamate, and thus produce an anti-excitotoxic effect, which may help alleviate depression. Due to this concerted and negative PR campaign tianeptine remains a little-known drug even in the countries where it has been approved for treating depression, and SSRI drugs still dominate the market for depression treatment. The studies below seem to demonstrate that SSRE is still a viable mechanism for treating depression, and thus again call the SSRI hypothesis into question. Namely, the studies below show that (naphtho)quinones such as vitamin K enhance the uptake or 5-HT into platelets due to their nature as oxidizing agents, and that despite (or because of?) this SSRE effect, quinones such as vitamin K have antidepressant effects, confirmed even in human trials.

https://pubmed.ncbi.nlm.nih.gov/1848980/

“…The effect of oxidant stress produced by redox cycling of substituted 1,4-naphthoquinones on the activity of platelet (Na(+)-K+)ATPase and the active transport of serotonin (5-HT) was studied. 2-Methyl-1,4-naphthoquinone (menadione) produced a concentration-dependent (0-100 microM) and time-dependent (2-20 min) stimulation of platelet 5-HT transport. Exogenous superoxide dismutase (250 units) and/or catalase (500 units) failed to block the stimulation. Fluoxetine (Prozac), an inhibitor of the platelet 5-HT transporter, blocked menadione-induced stimulation of 5-HT uptake as did ouabain, an inhibitor of platelet (Na(+)-K+)ATPase. The structure-activity relationship of select 1,4-naphthoquinones suggested that stimulation was due to redox cycling and not arylation. The kinetics of 5-HT transport revealed that menadione markedly increased the maximal rate of 5-HT transport (Vmax control = 20.6 +/- 2.0 pmol/10(8) platelets/4 min vs Vmax menadione = 46.4 +/- 3.9 pmol/10(8) platelets/4 min) but did not significantly alter the Km values. The activity of (Na(+)-K+)ATPase was determined by measuring the uptake of 86Rb+ into intact platelets. Menadione produced a concentration-dependent and time-dependent stimulation of platelet 86Rb+ uptake. These changes in platelet (Na(+)-K+)ATPase activity paralleled the changes observed in 5-HT transport and were inhibited in a concentration-dependent manner by ouabain. The data have shown that the redox cycling of 1,4-naphthoquinones caused an increase in (Na(+)-K+)ATPase activity that resulted in the stimulation of the rate of platelet 5-HT transport.”

https://pubmed.ncbi.nlm.nih.gov/41274421/

“…Depression is a chronic mental disorder characterized by alternations in emotions, thoughts, physical condition, and behavior. Using the natural product database Compound Combination-Oriented Natural Product Database with Unified Terminology (COCONUT) and the bioinformatics tool CODA (Context-Oriented Directed Associations), we screened and identified 1,4-naphthoquinone (1,4-NQ) as a promising candidate for depression treatment. Oral administration of 1,4-NQ attenuated the depressive-like behaviors in the open field test (OFT), elevated plus maze test (EPM) and forced swim test (FST) in a chronic restraint stress (CRS)-induced depressive-like mouse model. Real-time PCR analysis demonstrated that 1,4-NQ increased the mRNA levels of 5-HT1A and BDNF in the hippocampus of mouse brains. The expression level of glucocorticoid receptor (GR) in the hippocampus was increased by 1,4-NQ treatment in both CRS- and corticosterone-induced depression mouse models. We confirmed that 1,4-NQ has anti-neuroinflammatory efficacy by suppressing the levels of IL-6, TNF-α and IL-1β in LPS-stimulated BV2 microglial cell line. The western blot and real-time PCR analysis demonstrated that 1,4-NQ increased the level of GR in both the U-138 MG glial cell line and the SH-SY5Y neuronal cell line. In conclusion, 1,4-NQ is supposed to have anti-depressive efficacy by alleviating depressive-like behaviors through modulation of neuroinflammatory mediators and GR expression in the nervous system.”

https://pmc.ncbi.nlm.nih.gov/articles/PMC12113079/

“…Results: Most observational studies reported an inverse association between vitamin K intake or serum levels and depressive symptoms across diverse populations. One small RCT demonstrated modest improvements in depression scores following vitamin K2 (menaquinone-7) supplementation in women with polycystic ovary syndrome. Two preclinical studies using non-depression models reported behavioral improvements and reduced oxidative stress following vitamin K2 administration.”

https://pubmed.ncbi.nlm.nih.gov/35883082/

“…Consumption of Menaquinone-7 in comparison with the placebo capsules significantly improved depression status (P = 0.012). This clinical study reported the advantageous effect of Menaquinone-7 administration on depression status in PCOS patients.”

Author: haidut